Pierre Fabre Hopes To Enter US Cancer Space With Atara’s Ebvallo

Deal Snapshot: The French company already holds rights to the allogeneic T-cell therapy in much of the world, but will pay Atara $30m up front to obtain rights in the US, Canada and elsewhere.